Sequential design studies for antiepileptic drugs

Epilepsy and Behavior

Volumn 3, Issue 2, 2002, Pages 107-108

  Beydoun, Ahmad ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PLACEBO; REMACEMIDE;

ACCURACY; ANTICONVULSANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG WITHDRAWAL; EDITORIAL; FOCAL EPILEPSY; HUMAN; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; METHODOLOGY; PATIENT MONITORING; PROBABILITY; RANDOMIZATION; SAMPLE SIZE; SEQUENTIAL ANALYSIS; TONIC CLONIC SEIZURE; TREATMENT OUTCOME;

EID: 0036554695     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1006/ebeh.2002.0338     Document Type: Editorial

References (3)

1. Beydoun A, Milling C. J. Active-control comparative equivalency monotherapy trials in epilepsy: are they scientifically valid? Epilepsy Behav 2001;2:187-92.
2. Leber P. Hazards of inference: the active control investigation. Epilepsia 1989;30(Suppl. 1):S57-63.
3. Temple R. Problems in interpreting active control equivalence trials. Accountability Res 1996;4: 267-75.